TearClear
Disruptive eye health technology company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $11.8m Valuation: $110m | Late VC |
| Total Funding | 000k | ||
Related Content
TearClear, an ophthalmic pharmaceutical company established in 2012, is focused on advancing the treatment of glaucoma and other eye diseases through a novel drug delivery platform. The company was founded by Robert J. Dempsey, who has a background in building and leading life science companies. His experience in guiding ventures from early-stage development to commercial success directly informs TearClear's strategy. The core of the company's business is the development of preservative-free eye drops, addressing the negative side effects associated with preservatives commonly found in ophthalmic medications, such as benzalkonium chloride (BAK).
The company operates within the ophthalmic pharmaceutical market, targeting patients who suffer from chronic eye conditions that require long-term use of topical medications. TearClear's business model revolves around the clinical development and subsequent commercialization of its proprietary drug candidates. Revenue generation is anticipated from the sale of these therapies upon regulatory approval. The company has secured significant funding to advance its clinical programs, including a $22 million Series B financing round in 2019.
TearClear's lead product is TC-002 (Latanoprost Ophthalmic Solution), a treatment for glaucoma designed to be preservative-free at the time of administration. The product utilizes a unique filtration system built into the dropper bottle that removes preservatives from the solution just before it reaches the patient's eye. This approach maintains the sterility and stability of the medication within the bottle while delivering a preservative-free dose, which can reduce common side effects like ocular surface disease, redness, and irritation. The company successfully completed Phase 3 trials for TC-002, demonstrating that its preservative-free formulation is bioequivalent to the commercially available Xalatan®.
Keywords: ophthalmic pharmaceuticals, glaucoma treatment, drug delivery platform, preservative-free eye drops, ocular surface disease, benzalkonium chloride, latanoprost, clinical trials, topical medications, eye care